<DOC>
	<DOCNO>NCT01664169</DOCNO>
	<brief_summary>RATIONALE : Studying plasma sample patient pancreatic cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This research trial study biomarkers sample patient pancreatic cancer treat study CALGB-80303 .</brief_summary>
	<brief_title>Biomarkers Plasma Specimens From Patients Treated Study CALGB-80303</brief_title>
	<detailed_description>OBJECTIVES : - To determine whether observed predictive value plasma VEGF-A VEGF-R2 overall survival ( OS ) study BO17706 replicate study CALGB-80303 use Immunological Multiparameter Chip Technology ( IMPACT ) assay . - To determine whether observed predictive value plasma VEGF-A VEGF-R2 progression-free survival ( PFS ) , circulate biomarkers study BO17706 , replicate study CALGB-80303 use IMPACT assay . - To explore relationship efficacy biomarkers measure plasma sample . OUTLINE : The sample require study store CALGB Pathology Coordinating Office The Ohio State University patient enrol protocol CALGB-80303 . No additional sample require patient . The following marker analyze EDTA plasma sample use Immunological MultiParameter Chip Technology ( IMPACT ) Roche proprietary multiplex enzyme-linked immunosorbent assay ( ELISA ) platform : VEGF-A , VEGF-C , VEGF-R1 , VEGF-R2 , E-selectin , VEGF-R3 , IL-8 , bFGF , PDGF-C , ICAM-1 , PlGF .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Patients must register CALGB80303 Histologically cytologically confirm adenocarcinoma pancreas Locally advance metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>stage IIB pancreatic cancer</keyword>
</DOC>